Analysis of Significantly Different Bacteria. by Xu Jia (187142)

Variation of the most appropriate p value significance threshold with different ratios of the standard deviations and sample sizes. by Farrokh Habibzadeh (12256529)

Subjects:

Summary of significant treatment × time effect. by Wensheng Xiao (16557866)

Analysis of Significantly Different ARGs and Resistance Mechanisms. by Xu Jia (187142)

Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Baseline descriptive characteristics of trial participants with dizziness, by treatment group. by Anneli Peolsson (7867601)

Subjects:

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Linear covariate analysis of prognostically significant metabolites. Presenting the effect sizes of metabolites that showed significant differences among prognostic groups in ICU-treated COVID-19 patients.... by Emir Matpan (21655811)

“…<p>Linear covariate analysis of prognostically significant metabolites. Presenting the effect sizes of metabolites that showed significant differences among prognostic groups in ICU-treated COVID-19 patients. …”

Sediment particle size curve. by Hui Zhang (7197)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Study CONSORT diagram. by Benjamin R. Lewis (22279166)

Subjects:

Map of Zimbabwe highlighting the districts detected as persistent hotspots of <i>S. haematobium</i> prevalence (PPHS), persistent hotspots of decreased praziquantel efficacy (EPHS)... by Takafira Mduluza (39754)

Statins resulted in smaller neuronal soma size. by Shuk C. Tsoi (21192243)

“…Statin treatment decreased cell sizes in the larger cells more than in the smaller cells as seen in the greater divergence between lines plotted for larger cell somas (bottom panel). …”

Box plots showing baseline prevalence and mean egg count at pre-MDA1 in districts that were responders compared to those that were persistent hotspots of decreasing praziquantel ef... by Takafira Mduluza (39754)

S2 File - Factors influencing effective decrease of controlled attenuation parameters in metabolic-associated steatotic liver disease: A multilevel linear regression analysis at Va... by Sonsawan Sangprasert (22772538)